Location of Repository

Peptide Receptor Radionuclide Therapy (PRRT): Clinical Application

By Lisa Bodei and Giovanni Paganelli

Abstract

Neuroendocrine tumors are generally slow growing and are frequently discovered when metastatic spread has occurred. This leaves room for multiple treatments, individualized through a multidisciplinary approach that considers tumor type, extension, and related symptoms. In almost 15 years of academic phase II trials, PRRT with either 90Y-octreotide or 177Lu-octreotate proved to be efficient, with tumor responses in more than 30% of patients, symptom relief and QoL improvement, biomarker reduction, and, ultimately, an impact on survival

Topics: 177Lu-DOTATATE, 90Y-DOTATOC, Neuroendocrine tumor, PRRT, Biochemistry, Genetics and Molecular Biology (all), Chemistry (all), Medicine (all)
Publisher: Wiley Blackwell
Year: 2015
DOI identifier: 10.1002/9781119031659
OAI identifier: oai:iris.unife.it:11392/2374509
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://onlinelibrary.wiley.com... (external link)
  • http://hdl.handle.net/11392/23... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.